Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus anti-PD-1 alone, reduced tumor PD-L1 correlated with decreased pCREBDover, DE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued ...

Poster presented today in Boston shows direct anti-tumor activity in mesothelioma models, reduced tumor PD-L1 alongside decreased pCREB, and strong TT-4 monotherapy activity with added benefit in anti-PD-1 combinations; TT-4 remains on track for Q1 2026 first-patient dosingDover, DE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at th ...

Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeu ...